Cybin Inc. announced unprecedented 12-month efficacy data from its Phase 2 study of CYB003, a proprietary deuterated psilocin program for the adjunctive treatment of Major Depressive Disorder (MDD). The data showed that 100% of participants were responsive to treatment and 71% were in remission at 12 months after receiving just two 16 mg doses of CYB003.
The study also demonstrated a robust, long-term efficacy with approximately a 23-point reduction in the Montgomery-Asberg Depression Rating Scale (MADRS) score compared to baseline at 12 months. These findings validate the dosing regimen and confirm that CYB003's effects are highly durable, offering sustained relief for MDD patients.
CYB003 continued to be well-tolerated and demonstrated an excellent safety profile throughout the 12-month follow-up period. The company's Phase 3 PARADIGM multinational pivotal program, evaluating the efficacy and safety of CYB003, has been initiated, building on these strong Phase 2 results.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.